Trial Publications: ES2 and SC23

Wednesday, January 31, 2018
SC23: A Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases.
To compare the effectiveness of prophylactic dexamethasone versus placebo in protecting against radiation-induced pain flare associated with a single 8 Gy course of treatment by examining the difference in incidence of pain flare in the first 10 days after therapy

Multiple citations:

Chow S, Ding K, Wan BA, Brundage M, Meyer RM, Nabid A, Chabot P, Coulombe G, Ahmed S, Kuk J, Dar AR, Mahmud A, Fairchild A, Wilson CF, Wu JSY, Dennis K, DeAngelis C, Wong RKS, Zhu L, Chow E. Gender differences in pain and patient reported outcomes: a secondary analysis of the NCIC CTG SC. 23 randomized trial. Annals of Palliative Medicine; 6: S185-A194, 2017.

http://apm.amegroups.com/article/view/16293/18205

Furfari A, Wan BA, Ding K, Wong A, Zhu L, Bezjak A, Wong R, Wilson CF, DeAngelis C, Azad A, Chow E, Charames GS. Genetic biomarkers associated with changes in quality of life and pain following palliative radiotherapy in patients with bone metastases. Annals of Palliative Medicine; Vol 6, Supplement 2 (December 2017): Annals of Palliative Medicine 6: S248-S256, 2017.

http://apm.amegroups.com/article/view/16779/18214

Furfari A, Wan BA, Ding K, Wong A, Zhu L, Bezjak A, Wong R, Wilson CF, DeAngelis C, Azad A, Chow E, Charames GS. Genetic biomarkers associated with pain flare and dexamethasone response following palliative radiotherapy in patients with painful bone metastases. Annals of Palliative Medicine; 6: S240-S247, 2017.

http://apm.amegroups.com/article/view/16557/18212

Furfari A, Wan BA, Ding K, Wong A, Zhu L, Bezjak A, Wong R, Wilson CF, DeAngelis C, Azad A, Chow E, Charames GS. Genetic biomarkers associated with response to palliative radiotherapy in patients with painful bone metastases. Annals of Palliative Medicine; 6: S233-S239, 2017.

 http://apm.amegroups.com/article/view/16866/18211

 


 

ES2: Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01)
A short course of radiotherapy is commonly prescribed for palliative relief of malignant dysphagia in patients with incurable oesophageal cancer. Comparing chemoradiotherapy with radiotherapy alone for dysphagia relief in the palliative setting.
 
Penniment MG, De Ieso PB, Harvey JA, Stephens S, Au HJ, O'Callaghan CJ, Kneebone A, Ngan SY, Ward IG, Roy R, Smith JG, Nijjar T, Biagi JJ, Mulroy LA, Wong R. Palliative chemoradiotherapy versus radiotherapy alone for dysphagia in advanced oesophageal cancer: a multicentre randomised controlled trial (TROG 03.01). The Lancet Gastroenterology & Hepatology 3: 114-24, 2018.

https://www.sciencedirect.com/science/article/pii/S2468125317303631?via%3Dihub